Trials / Completed
CompletedNCT00569803
Subcutaneous Pharmacokinetics of Belatacept
Pharmacokinetics, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | belatacept | single dose, 116 days |
| DRUG | Placebo | Subcutaneous injection of placebo solution (product ID: 224818-N000- 029) |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2007-12-07
- Last updated
- 2016-09-22
- Results posted
- 2016-08-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00569803. Inclusion in this directory is not an endorsement.